WO2008059368A3 - Fused 2-amino pyrimidine compounds and their use for the treatment of cancer - Google Patents

Fused 2-amino pyrimidine compounds and their use for the treatment of cancer Download PDF

Info

Publication number
WO2008059368A3
WO2008059368A3 PCT/IB2007/003532 IB2007003532W WO2008059368A3 WO 2008059368 A3 WO2008059368 A3 WO 2008059368A3 IB 2007003532 W IB2007003532 W IB 2007003532W WO 2008059368 A3 WO2008059368 A3 WO 2008059368A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
fused
pyrimidine compounds
amino pyrimidine
Prior art date
Application number
PCT/IB2007/003532
Other languages
French (fr)
Other versions
WO2008059368A2 (en
Inventor
Pei-Pei Kung
Jerry Jialun Meng
Original Assignee
Pfizer Prod Inc
Pei-Pei Kung
Jerry Jialun Meng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Pei-Pei Kung, Jerry Jialun Meng filed Critical Pfizer Prod Inc
Publication of WO2008059368A2 publication Critical patent/WO2008059368A2/en
Publication of WO2008059368A3 publication Critical patent/WO2008059368A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention is directed to 2-aminopyrimidine compounds and pharmaceutically acceptable salts thereof, their synthesis and their use as HSP-90 inhibitors, for the treatment of cancer.
PCT/IB2007/003532 2006-11-17 2007-11-09 Fused 2-amino pyrimidine compounds and their use for the treatment of cancer WO2008059368A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86637306P 2006-11-17 2006-11-17
US60/866,373 2006-11-17
US98493807P 2007-11-02 2007-11-02
US60/984,938 2007-11-02

Publications (2)

Publication Number Publication Date
WO2008059368A2 WO2008059368A2 (en) 2008-05-22
WO2008059368A3 true WO2008059368A3 (en) 2008-10-30

Family

ID=39311075

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003532 WO2008059368A2 (en) 2006-11-17 2007-11-09 Fused 2-amino pyrimidine compounds and their use for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2008059368A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987743A1 (en) 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Purine derivatives and their use as immunosuppressive agents
AR077405A1 (en) 2009-07-10 2011-08-24 Sanofi Aventis DERIVATIVES OF INDOL INHIBITORS OF HSP90, COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CANCER
FR2949467B1 (en) 2009-09-03 2011-11-25 Sanofi Aventis NOVEL 5,6,7,8-TETRAHYDROINDOLIZINE DERIVATIVES INHIBITORS OF HSP90, COMPOSITIONS CONTAINING SAME AND USE THEREOF
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
EP2691399B1 (en) * 2011-03-28 2016-07-13 F.Hoffmann-La Roche Ag Thiazolopyrimidine compounds
CN103443107B (en) * 2011-03-28 2016-04-20 弗·哈夫曼-拉罗切有限公司 Thiazolopyrimidine compound
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR20140110066A (en) 2012-01-10 2014-09-16 에프. 호프만-라 로슈 아게 Thienopyrimidine compounds
ES2827233T3 (en) * 2013-01-18 2021-05-20 Guangzhou Maxinovel Pharmaceuticals Co Ltd Five- and six-membered heterocyclic compound, and method of preparation, pharmaceutical composition and use thereof
ES2954453T3 (en) * 2014-06-13 2023-11-22 Yuma Therapeutics Inc Pyrimidine compounds and methods using the same
TW201822637A (en) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 Substituted sulfonamides for controlling animal pests
JP2023501978A (en) 2019-11-07 2023-01-20 バイエル・アクチエンゲゼルシヤフト Substituted Sulfonylamides for Animal Pest Control
GB201919213D0 (en) * 2019-12-23 2020-02-05 Ucb Biopharma Sprl Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
GB201919216D0 (en) 2019-12-23 2020-02-05 UCB Biopharma SRL Tetrahydrobenzo-quinoline sulfonamides derivative compounds
WO2022089449A1 (en) * 2020-10-26 2022-05-05 山东大学 PREPARATION OF SPECIFIC HEAT SHOCK PROTEIN 90α SUBTYPE INHIBITOR AND USE THEREOF

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001097979A (en) * 1999-07-28 2001-04-10 Takeda Chem Ind Ltd Condensed heterocyclic compound, and method of production and application thereof
WO2005021552A1 (en) * 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
WO2006008503A1 (en) * 2004-07-20 2006-01-26 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
WO2006090094A1 (en) * 2005-02-28 2006-08-31 Vernalis R & D Ltd Pyrimidothiophene compounds for use as hsp90 inhibitors
WO2007084560A2 (en) * 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001097979A (en) * 1999-07-28 2001-04-10 Takeda Chem Ind Ltd Condensed heterocyclic compound, and method of production and application thereof
WO2005021552A1 (en) * 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
WO2006008503A1 (en) * 2004-07-20 2006-01-26 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
WO2006090094A1 (en) * 2005-02-28 2006-08-31 Vernalis R & D Ltd Pyrimidothiophene compounds for use as hsp90 inhibitors
WO2007084560A2 (en) * 2006-01-17 2007-07-26 Signal Pharmaceuticals, Llc INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICOLAUS B J R: "Symbiotic Approach to Drug Design", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1 January 1983 (1983-01-01), pages 173 - 186, XP002197412 *

Also Published As

Publication number Publication date
WO2008059368A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
WO2008059368A3 (en) Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
MX2009008386A (en) 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer.
WO2007049041A8 (en) 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
MX2009010037A (en) Aminopyrimidines useful as kinase inhibitors.
MX2009009590A (en) Aminopyrimidines useful as inhibitors of protein kinases.
CL2012000163A1 (en) Compounds derived from quinazoline or pyrido [2,3-d] pyrimidine, autophagy inhibitors; pharmaceutical composition; and its use for the treatment of cancer, pancreatitis, neurodegeneration, among others.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
IL192763A (en) Pyrimidine derivatives, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of cancer
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
WO2009021992A3 (en) Fused bicyclic pyrimidines
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
NZ702571A (en) 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
MX2009006690A (en) Aminopyrimidines useful as inhibitors of protein kinases.
TW200734327A (en) Aminopyrimidines useful as kinase inhibitors
MX2009011811A (en) Aminopyrimidines useful as kinase inhibitors.
MX2009004807A (en) Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2009010127A (en) N-heterocyclic compounds useful as inhibitors of janus kinases.
WO2007081630A3 (en) Substituted pyrimidinyl kinase inhibitors
AP2886A (en) 6.7-Dialkoxy quinazoline derivatives useful for treatment of cancer related disorders
MX2009011059A (en) Aminopyrimidines useful as kinase inhibitors.
WO2008033745A3 (en) Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07825690

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07825690

Country of ref document: EP

Kind code of ref document: A2